Cash and equivalents (GAAP) totaled $13.1 million as of Q2 2025. These 10 stocks could mint the next wave of millionaires › Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ('Adial” or the 'Company”), a clinical-stage biopharmaceutical company focused on ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

Operator: Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing ...

Q2 2025 Earnings Call Transcript August 13, 2025 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

Q2 2025 Earnings Call Transcript August 13, 2025 BiomX Inc. beats earnings expectations. Reported EPS is $-0.19, expectations ...

Key Points Collaboration and license revenue (GAAP) for Q2 2025 was $8.1 million but missed Q2 2025 GAAP revenue estimates by $0.11 million. Net loss (GAAP) widened to $15.8 million, with increased ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...